Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents.
Am J Obstet Gynecol
; 208(1): 64.e1-7, 2013 Jan.
Article
em En
| MEDLINE
| ID: mdl-23063019
ABSTRACT
OBJECTIVE:
The importance of maternal autoantibody levels in congenital heart block and elucidation of maternal factors that may reduce disease burden require further clarification. STUDYDESIGN:
Pregnancies complicated by maternal anti-Ro antibodies from 2007 through 2011 were retrospectively reviewed.RESULTS:
In all, 33 women were followed up throughout pregnancy. Semiquantitative maternal anti-La levels were significantly higher in pregnancies complicated by fetal heart block of any degree (median difference, 227.5; P = .04), but there was no difference in maternal anti-Ro levels. In all, 94% of fetuses maintained normal conduction when the mother was treated with hydroxychloroquine or daily prednisone therapy throughout pregnancy, compared to 59% in the untreated group (odds ratio, 0.1; P = .04).CONCLUSION:
Pregnancies complicated by fetal heart block did not have higher levels of maternal anti-Ro antibodies. Maternal anti-La level may be a useful predictor of fetal heart block. Maternal treatment with either hydroxychloroquine or daily low-dose prednisone throughout pregnancy may provide a protective effect.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Prednisona
/
Anticorpos Antinucleares
/
Bloqueio Cardíaco
/
Hidroxicloroquina
/
Anti-Inflamatórios
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article